Healthcare staff caring for patients with cancer must have access to high quality and generalizable data regarding the toxicities and repercussions of cancer treatments
Onconephrology, the intersection between oncology and nephrology, is a rapidly evolving field that has gained considerable interest over the past 15 years. Cancer treatments are often highly effective at targeting cancer cells but can lead to unexpected side effects, including acute kidney injury, hypertension, and electrolyte abnormalities. These kidney related toxicities can lead to temporary or permanent discontinuation of potentially lifesaving cancer treatments. Additionally, patients with cancer are living longer and could develop chronic kidney disease after bouts of acute kidney injury, thereby jeopardizing their eligibility for future treatments, in addition to placing them at increased risk of cardiovascular disease and death.1 It is therefore essential that nephrologists, oncologists, and other providers caring for patients with cancer have access to high quality and generalizable data regarding these toxicities and their repercussions.
Despite some progress toward characterizing and understanding the kidney related toxicities associated with cancer treatments, …